Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kymab has entered into Kymouse antibody discovery agreement with Novo Nordisk for the discovery and commercialization of therapeutic monoclonal antibody drugs to treat various human diseases.
Subscribe to our email newsletter
According to the deal, Novo Nordisk has access to the Kymouse HK and Kymouse HL transgenic human antibody mouse strains, the combination of which are used to create various human antibodies.
Kymab chief business officer Dr. Tom Shepherd said, "Novo Nordisk’s expertise and track record in developing biological therapeutics coupled with its existing therapeutic antibody discovery infrastructure makes it an ideal partner for Kymab."
Antibodies with human heavy and lambda light chains are produced using Kymouse HL strain while Kymouse HK generates antibodies with human heavy and kappa light chains.
Novo Nordisk immunotechnology head, vice president Hanne Risager Romedahl said, "Kymab’s highly innovative and technically advanced Kymouse platform is an excellent fit with our existing therapeutic antibody discovery capability."
The agreement includes platform licence fees, development milestone payments for drug candidates and sales based royalties.
Other financial details were not revealed.